Therapy News and Research

RSS

FDA clears Neurelis IND to commence NRL-1 clinical trials for acute breakthrough seizures

Neurelis, Inc. today announced that the United States Food and Drug Administration (FDA) has cleared an Investigational New Drug application (IND) to commence clinical trials advancing the development of NRL-1 for the treatment of acute breakthrough seizures.

7 Feb 2012

Tips to combat milder winter doldrums

Shorter days and colder weather can lead to a loss of energy for many people. Summoning the motivation to perform daily tasks can be a challenge. Some people even suffer episodes of clinical depression triggered by the change in seasons, a condition called "seasonal affective disorder."

7 Feb 2012

CRT2012 conference to discuss PCI procedures using CorPath 200 System

Corindus Vascular Robotics, a leading developer of precision vascular robotics, today announced that Giora Weisz, M.D., Director of Clinical Cardiovascular Research at the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital/Columbia University Medical Center and Associate Professor of medicine at Columbia University College of Physicians and Surgeons, New York, N.Y. will present his personal experience using the CorPath 200 System as part of the CorPath PRECISE Trial during a scientific presentation "Cath Lab of the Future: Robotics" at the Cardiovascular Research Technologies' annual meeting, CRT2012.

7 Feb 2012

Preliminary results from Remedy Pharmaceuticals' RP-1127 Phase 2 trial on stroke

Each year, over 700,000 people in the United States suffer a stroke. For most, medical science can do very little. Some will die; a number will suffer debilitating aftereffects. Now, preliminary results of a Phase 2 clinical trial using Remedy Pharmaceuticals' new drug, RP-1127, presented at the 2012 International Stroke Conference in New Orleans on February 2, offer hope to many of these patients.

6 Feb 2012

Vigorous exercise triggers MSC accumulation in skeletal muscle

University of Illinois researchers determined that an adult stem cell present in muscle is responsive to exercise, a discovery that may provide a link between exercise and muscle health. The findings could lead to new therapeutic techniques using these cells to rehabilitate injured muscle and prevent or restore muscle loss with age.

6 Feb 2012

Combination of ICS and LABA appears to reduce severe asthma attacks

A Henry Ford Hospital study has found that using two types of common asthma medications in combination reduces severe asthma attacks.

6 Feb 2012

Viewpoints: Komen's retreat; Romney's selected support of Medicare cuts; Heritage refuses blame for individual mandate

A group like Komen only has the quality service it provides and goodwill garnered over the years to encourage donations and support. Its trademark pink is not as bold as before. For the moment, it seems drab and faded.

6 Feb 2012

Emergent Financial Group raises $11.8M for Tenex Health

Emergent Financial Group, Inc. today announced the completion of a $11.8 million private placement transaction for Tenex Health Inc., a California-based medical technology company developing the FAST Procedure (Focused Aspiration of Scar Tissue) for the treatment of tendon injuries.

6 Feb 2012

Orexigen reaches SPA agreement for Contrave outcomes trial with FDA

Orexigen Therapeutics, Inc. today announced that it has reached agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment for the Contrave outcomes trial.

6 Feb 2012

Takeda launches EDARBYCLOR in the U.S. for treatment of hypertension

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., announced EDARBYCLOR (azilsartan medoxomil and chlorthalidone) is now available by prescription in U.S. pharmacies for the treatment of hypertension to lower blood pressure in adults.

6 Feb 2012

Clinuvel submits SCENESSE MAA to EMA for treatment of erythropoietic protoporphyria

Clinuvel Pharmaceuticals Limited today announced that it has submitted a marketing authorisation application (MAA) for its first-in-class drug SCENESSE (afamelanotide 16mg implant) to the European Medicines Agency.

6 Feb 2012

Medicaid news: Kansas insurer says 'no' to Medicaid

The state of Kansas' largest insurance company has decided it doesn't want to participate in Gov. Sam Brownback's plan to move Medicaid patients into privatized managed-care programs. In a letter addressed "Dear provider," Angie Strecker, director of institutional relations for Blue Cross Blue Shield of Kansas, said the insurer "has decided not to submit a proposal to the state to be a Medicaid contractor."

6 Feb 2012

Tennessee Gov. declares February as 'St. Jude Month'

In 1962, St. Jude Children's Research Hospital opened its doors amid an emotionally charged debate regarding how to treat childhood cancer. At that time, few children with the most common form of childhood cancer survived, and many physicians believed treatment was futile. St. Jude physicians and researchers took a radically different approach, and these efforts proved pivotal in changing the way the world treats childhood cancer.

6 Feb 2012

New stent retriever procedure safe, effective for patients with stroke

A new way of opening blocked arteries in the brain using a removable stent system in people suffering strokes brought remarkably positive results in how those patients recovered from the strokes, according to a study presented this morning at the American Stroke Association's annual conference in New Orleans.

4 Feb 2012

CT-guided catheters carry t-PA to shrink clots in patients with ICH

Johns Hopkins neurologists report success with a new means of getting rid of potentially lethal blood clots in the brain safely without cutting through easily damaged brain tissue or removing large pieces of skull. The minimally invasive treatment, they report, increased the number of patients with intracerebral hemorrhage (ICH) who could function independently by 10 to 15 percent six months following the procedure.

4 Feb 2012

Aspirin plus clopidogrel unlikely to prevent recurrent strokes and may increase risk of death, bleeding

The anti-blood clot regimen that adds the drug clopidogrel (Plavix) to aspirin treatment is unlikely to prevent recurrent strokes and may increase the risk of bleeding and death in patients with subcortical stroke according to late-breaking research presented at the American Stroke Association's International Stroke Conference 2012.

4 Feb 2012

Mineral and multivitamin supplements can lower risk of colon cancer

Could the use of vitamin and mineral supplements in a regular diet help to reduce the risk of colon cancer and protect against carcinogens? A study published in the Canadian Journal of Physiology and Pharmacology (CJPP) found that rats given regular multivitamin and mineral supplements showed a significantly lower risk of developing colon cancer when they were exposed to carcinogens.

4 Feb 2012

New editorial offers clarity on confusing drug and alcohol addiction terminology

A new editorial released this week offers clarity and structure on confusing drug and alcohol addiction terminology for prescribers, users and regulators. "Through a glass darkly: can we improve clarity about mechanism and aims of medications in drug and alcohol treatments?" is published in the Journal of Psychopharmacology, the official journal of the British Association for Psychopharmacology, published by SAGE.

4 Feb 2012

Aspirin and warfarin similar in preventing deaths and strokes in heart failure patients

In the largest and longest head-to-head comparison of two anti-clotting medications, warfarin and aspirin were similar in preventing deaths and strokes in heart failure patients with normal heart rhythm, according to late-breaking research presented at the American Stroke Association's International Stroke Conference 2012.

4 Feb 2012

New experimental device effectively removes blood clots in stroke patients

An experimental device for removing blood clots in stroke patients dramatically outperformed the standard mechanical treatment, according to research presented by UCLA Stroke Center director Dr. Jeffrey L. Saver at the American Stroke Association's 2012 international conference in New Orleans on Feb. 3.

4 Feb 2012